$0.16
-0.01 (-4.18%)
Open$0.15
Previous Close$0.16
Day High$0.16
Day Low$0.13
52W High$1.77
52W Low$0.16
Volume—
Avg Volume3.69M
Market Cap41.67M
P/E Ratio—
EPS$-1.71
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+7,454.6% upside
Current
$0.16
$0.16
Target
$11.77
$11.77
$8.46
$11.77 avg
$14.40
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 156.93M | 35.79M | 31.57M |
| Net Income | -349,674,517 | 827.5K | 932.2K |
| Profit Margin | -222.8% | 2.3% | 3.0% |
| EBITDA | -237,225,462 | 1.82M | 1.58M |
| Free Cash Flow | — | 629.7K | 483.5K |
| Rev Growth | — | +6.8% | +6.0% |
| Debt/Equity | 0.84 | 0.61 | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |